EA201490825A1 - Tdp-43-специфически связывающие молекулы - Google Patents
Tdp-43-специфически связывающие молекулыInfo
- Publication number
- EA201490825A1 EA201490825A1 EA201490825A EA201490825A EA201490825A1 EA 201490825 A1 EA201490825 A1 EA 201490825A1 EA 201490825 A EA201490825 A EA 201490825A EA 201490825 A EA201490825 A EA 201490825A EA 201490825 A1 EA201490825 A1 EA 201490825A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- tdp
- binding molecules
- specific binding
- specifically binding
- variants
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Radiology & Medical Imaging (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Optics & Photonics (AREA)
- Psychology (AREA)
Abstract
Целью изобретения является создание новых TDP-43-специфически связывающих молекул, в том числе полипептидов, таких как человеческие антитела, а также фрагментов, производных и их вариантов. Предложены также способы, связанные с этими TDP-43-специфически связывающими молекулами. Анализы, наборы и твердые носители, связанные с TDP-43-специфически связывающими молекулами, в том числе полипептидами, такими как человеческие антитела, также раскрыты. TDP-43-специфически связывающие молекулы, антитела, цепь иммуноглобулина(ов), а также связывающие фрагменты, производные и их варианты могут быть использованы в фармацевтических и диагностических составов для TDP-43 ориентированной иммунотерапии и диагностики, соответственно.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161553113P | 2011-10-28 | 2011-10-28 | |
PCT/IB2012/002905 WO2013061163A2 (en) | 2011-10-28 | 2012-10-26 | Tdp-43 specific binding molecules |
Publications (3)
Publication Number | Publication Date |
---|---|
EA201490825A1 true EA201490825A1 (ru) | 2015-01-30 |
EA201490825A8 EA201490825A8 (ru) | 2016-09-30 |
EA032003B1 EA032003B1 (ru) | 2019-03-29 |
Family
ID=47720540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201490825A EA032003B1 (ru) | 2011-10-28 | 2012-10-26 | Анти-tdp-43 антитело |
Country Status (18)
Country | Link |
---|---|
US (3) | US9587014B2 (ru) |
EP (2) | EP2771359B1 (ru) |
JP (3) | JP6240611B2 (ru) |
KR (2) | KR101961508B1 (ru) |
CN (1) | CN104159918B (ru) |
AU (1) | AU2012327211C9 (ru) |
BR (1) | BR112014010161B1 (ru) |
CA (2) | CA3112082A1 (ru) |
CL (1) | CL2014001074A1 (ru) |
EA (1) | EA032003B1 (ru) |
ES (1) | ES2883212T3 (ru) |
HK (1) | HK1201846A1 (ru) |
IL (2) | IL232219B (ru) |
MX (2) | MX357678B (ru) |
MY (1) | MY167795A (ru) |
SG (1) | SG11201401735WA (ru) |
WO (1) | WO2013061163A2 (ru) |
ZA (1) | ZA201403680B (ru) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL199534A (en) | 2007-01-05 | 2013-01-31 | Univ Zuerich | An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses. |
CN104159918B (zh) | 2011-10-28 | 2019-09-13 | 生物国际神经系统科学公司 | Tdp-43特异性结合分子 |
EP3008083B1 (en) | 2013-06-11 | 2021-06-30 | Paul Scherrer Institut | Method for determining mutateable ligand-gpcr binding at single amino acid resolution and pairs of mutated ligand and gpcr |
EP3099712A4 (en) * | 2014-01-31 | 2017-11-08 | Arizona Board of Regents on behalf of Arizona State University | Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein tdp-43 |
CN104497121A (zh) * | 2014-08-29 | 2015-04-08 | 苏州顺升桥生物科技有限公司 | 淀粉样蛋白tdp-43及其用途 |
TWI592423B (zh) * | 2014-10-03 | 2017-07-21 | 中央研究院 | 可辨識致病性tdp-43之抗體及其用途 |
JP2018503596A (ja) | 2014-10-03 | 2018-02-08 | アカデミア シニカAcademia Sinica | Tdp−43の病理学的形態に対する抗体及びその使用 |
WO2016053610A1 (en) * | 2014-10-03 | 2016-04-07 | Academia Sinica | Antibodies against pathological forms of tdp-43 and uses thereof |
MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
WO2017111166A1 (ja) * | 2015-12-25 | 2017-06-29 | 国立大学法人東京農工大学 | Tdp-43細胞内存在量関連疾患治療剤 |
US11340225B2 (en) | 2016-03-14 | 2022-05-24 | Biogen International Neuroscience Gmbh | Antibody-dependent cell-mediated phagocytosis assay for reliably measuring uptake of aggregated proteins |
US20190330318A1 (en) | 2016-07-25 | 2019-10-31 | Biogen Ma Inc. | Anti-hspa5 (grp78) antibodies and uses thereof |
WO2018112362A1 (en) | 2016-12-16 | 2018-06-21 | Biogen Ma Inc. | Stabilized proteolytically activated growth differentiation factor 11 |
MY200609A (en) * | 2017-03-14 | 2024-01-05 | Five Prime Therapeutics Inc | Antibodies binding to vista at acidic ph |
JP2020522475A (ja) * | 2017-05-30 | 2020-07-30 | ザ ユニヴァーシティ オブ ブリティッシュ コロンビア | Tdp−43のrna認識モチーフ1(rrm1)中のエピトープ、およびそれらに対するミスフォールディング選択的抗体 |
CA3073066A1 (en) | 2017-08-22 | 2019-02-28 | Biogen Ma Inc. | Pharmaceutical compositions containing anti-beta amyloid antibodies |
US11246857B2 (en) * | 2017-12-14 | 2022-02-15 | The Johns Hopkins University | Anti-fungal inhibitors |
EP3724232A4 (en) | 2017-12-14 | 2021-12-15 | The University of Ottawa | EXOSOME PACKAGING AND TARGETED AUTOPHAGY |
KR20200106525A (ko) * | 2018-01-05 | 2020-09-14 | 에이씨 이뮨 에스.에이. | 미스폴딩된 tdp-43 결합 분자 |
CN112236523A (zh) * | 2018-03-16 | 2021-01-15 | 国立大学法人滋贺医科大学 | 降解和去除异常tdp-43的抗体片段 |
TW202019398A (zh) * | 2018-06-28 | 2020-06-01 | 張翔毓 | 用於治療或預防構形疾病之方法及藥物篩選方法 |
CA3117409A1 (en) | 2018-10-29 | 2020-05-07 | Biogen Ma Inc. | Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport |
JP2022512388A (ja) * | 2018-12-14 | 2022-02-03 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | ミスフォールドtdp-43に対する抗体およびその使用方法 |
SG11202112453TA (en) | 2019-05-23 | 2021-12-30 | Ac Immune Sa | Anti-tdp-43 binding molecules and uses thereof |
CA3150627A1 (en) * | 2019-08-12 | 2021-02-18 | Macquarie University | Compositions and methods for treatment |
GB202004863D0 (en) * | 2020-04-02 | 2020-05-20 | Univ Oxford Innovation Ltd | Method |
JP2023524414A (ja) | 2020-04-28 | 2023-06-12 | ソラ・バイオサイエンシズ・エルエルシー | Tdp-43プロテイノパチーの処置のための組成物および方法 |
AU2021265165A1 (en) * | 2020-04-29 | 2022-12-08 | Promis Neurosciences Inc. | Single chain antibodies and intrabodies to misfolded TDP-43 and methods of use |
EP4196162A1 (en) | 2020-08-14 | 2023-06-21 | AC Immune SA | Humanized anti-tdp-43 binding molecules and uses thereof |
JP2023551542A (ja) | 2020-11-30 | 2023-12-08 | エニグマ バイオインテリジェンス,インコーポレイテッド | アルツハイマー病の非侵襲的評価 |
CN112920264B (zh) * | 2021-02-08 | 2022-07-05 | 武汉大学 | Tdp-43蛋白的o-糖基化突变体及其应用 |
JP6961278B1 (ja) * | 2021-03-10 | 2021-11-05 | 国立研究開発法人量子科学技術研究開発機構 | 生体試料中のtdp−43を測定する方法及び装置 |
AU2022282368A1 (en) * | 2021-05-27 | 2023-11-30 | Mayo Foundation For Medical Education And Research | Methods and materials for treating proteinopathies |
US20230107901A1 (en) * | 2021-10-01 | 2023-04-06 | University Of Utah Research Foundation | Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy |
WO2023099788A1 (en) | 2021-12-03 | 2023-06-08 | Neurimmune Ag | Novel potency assay for antibody-based drugs and useful means therefor |
TW202342519A (zh) | 2022-02-16 | 2023-11-01 | 瑞士商Ac 免疫有限公司 | 人源化抗tdp-43結合分子及其用途 |
WO2023194565A1 (en) * | 2022-04-08 | 2023-10-12 | Ac Immune Sa | Anti-tdp-43 binding molecules |
WO2023205579A1 (en) * | 2022-04-18 | 2023-10-26 | The Regents Of The University Of California | Compositions and methods for disrupting pathological aggregates |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5688511A (en) * | 1991-11-05 | 1997-11-18 | Board Of Regents, The University Of Texas System | Cellular protein TDP-43 and regulation of HIV-1 gene expression |
CA2253633A1 (en) * | 1997-12-03 | 1999-06-03 | Boehringer Mannheim Corporation | Complex specific antibodies, method of preparation and uses thereof |
US8354236B2 (en) * | 2006-09-29 | 2013-01-15 | The Trustees Of The University Of Pennsylvania | Detection of neurodegenerative disease |
CA2764852C (en) | 2007-01-05 | 2018-09-18 | University Of Zurich | Method of providing disease-specific binding molecules and targets |
WO2008151055A1 (en) | 2007-06-01 | 2008-12-11 | Mayo Foundation For Medical Education And Research | Diagnosing neurodegenerative diseases |
JP5439176B2 (ja) | 2007-07-06 | 2014-03-12 | 公益財団法人東京都医学総合研究所 | Tdp−43凝集物に特異的に結合する抗体 |
CA2713871C (en) * | 2008-02-01 | 2018-05-22 | Washington University In St. Louis | Sequences associated with tdp-43 proteinopathies and methods of using the same |
SI2370466T1 (sl) | 2008-12-19 | 2015-11-30 | Biogen International Neuroscience Gmbh | Človeška avtoprotitelesa proti alfa-sinukleinu |
CN101634656A (zh) * | 2009-08-21 | 2010-01-27 | 武汉三鹰生物技术有限公司 | 人tdp-43的单抗包被酶标板的制法及elisa检测试剂盒 |
CN104159918B (zh) | 2011-10-28 | 2019-09-13 | 生物国际神经系统科学公司 | Tdp-43特异性结合分子 |
-
2012
- 2012-10-26 CN CN201280064098.6A patent/CN104159918B/zh active Active
- 2012-10-26 EP EP12824769.9A patent/EP2771359B1/en active Active
- 2012-10-26 MX MX2014005048A patent/MX357678B/es active IP Right Grant
- 2012-10-26 AU AU2012327211A patent/AU2012327211C9/en active Active
- 2012-10-26 KR KR1020147014139A patent/KR101961508B1/ko active IP Right Grant
- 2012-10-26 CA CA3112082A patent/CA3112082A1/en active Pending
- 2012-10-26 BR BR112014010161-2A patent/BR112014010161B1/pt active IP Right Grant
- 2012-10-26 EP EP21173838.0A patent/EP3964524A1/en not_active Withdrawn
- 2012-10-26 CA CA2853412A patent/CA2853412C/en active Active
- 2012-10-26 US US14/354,404 patent/US9587014B2/en active Active
- 2012-10-26 SG SG11201401735WA patent/SG11201401735WA/en unknown
- 2012-10-26 ES ES12824769T patent/ES2883212T3/es active Active
- 2012-10-26 EA EA201490825A patent/EA032003B1/ru unknown
- 2012-10-26 WO PCT/IB2012/002905 patent/WO2013061163A2/en active Application Filing
- 2012-10-26 KR KR1020187035073A patent/KR102032080B1/ko active IP Right Grant
- 2012-10-26 MY MYPI2014001180A patent/MY167795A/en unknown
- 2012-10-26 JP JP2014537750A patent/JP6240611B2/ja active Active
-
2014
- 2014-04-24 IL IL23221914A patent/IL232219B/en active IP Right Grant
- 2014-04-25 MX MX2018008680A patent/MX2018008680A/es unknown
- 2014-04-25 CL CL2014001074A patent/CL2014001074A1/es unknown
- 2014-05-20 ZA ZA2014/03680A patent/ZA201403680B/en unknown
-
2015
- 2015-03-03 HK HK15102148.0A patent/HK1201846A1/xx unknown
-
2016
- 2016-11-04 US US15/343,450 patent/US10259866B2/en active Active
-
2017
- 2017-06-28 JP JP2017126314A patent/JP6417451B2/ja active Active
-
2018
- 2018-09-19 JP JP2018174683A patent/JP6652609B2/ja active Active
-
2019
- 2019-02-25 US US16/284,602 patent/US11091540B2/en active Active
- 2019-10-28 IL IL270223A patent/IL270223B/en active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201490825A8 (ru) | Tdp-43-специфически связывающие молекулы | |
PH12021550083A1 (en) | Human anti-tau antibodies | |
EA201390453A1 (ru) | Человеческие анти-тау антитела | |
EA201190041A1 (ru) | Человеческие аутоантитела против альфа-синуклеина | |
EA201591091A1 (ru) | Антигенсвязывающие белки для bcma | |
EA201490677A1 (ru) | Связывающие антиген cd27l белки | |
EA201492149A1 (ru) | St2-антигенсвязывающие белки | |
EA201590459A1 (ru) | Специфические антитела к островковому амилоидному полипептиду человека (hiapp) и их применение | |
ECSP12012272A (es) | Proteínas que se unen al tnf-? | |
EA201391761A1 (ru) | Анти-альфа-синуклеинсвязывающие молекулы | |
EA201390669A1 (ru) | Способы и композиции для иммунотерапии заболеваний нервной системы | |
EA201270571A1 (ru) | Человеческие il-23-антигенсвязывающие белки | |
EA201991704A3 (ru) | Моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
EA201401065A1 (ru) | Ang2-связывающие молекулы | |
EA202092790A1 (ru) | Происходящее от человека антитело к дипептидным повторам (dpr) | |
DOP2012000266A (es) | PROTEÍNAS QUE SE UNEN AL TNF-a | |
MX360580B (es) | Autoanticuerpos humanos anti-alfa-sinucleina. |